PMC:7408073 / 252-442 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-UBERON

    {"project":"LitCovid-PD-UBERON","denotations":[{"id":"T4","span":{"begin":137,"end":140},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"}],"text":" in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to h"}

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"25","span":{"begin":4,"end":12},"obj":"Species"},{"id":"26","span":{"begin":25,"end":35},"obj":"Species"},{"id":"31","span":{"begin":13,"end":21},"obj":"Disease"}],"attributes":[{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Tax:9606"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Tax:2697049"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to h"}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":25,"end":33},"obj":"Disease"},{"id":"T3","span":{"begin":25,"end":29},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":" in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to h"}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":137,"end":140},"obj":"Chemical"},{"id":"T5","span":{"begin":141,"end":159},"obj":"Chemical"},{"id":"T6","span":{"begin":149,"end":159},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_76932"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":" in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to h"}